A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
Kulke, M.H.; Ruszniewski, P.; Van Cutsem, E.; Lombard-Bohas, C.; Valle, J.W.; De Herder, W.W.; Pavel, M.; Degtyarev, E.; Brase, J.C.; Bubuteishvili-Pacaud, L.; Voi, M.; Salazar, R.; Borbath, I.; Fazio, N.; Smith, D.; Capdevila, J.; Riechelmann, R.P.; Yao, J.C.
Annals of Oncology Official Journal of the European Society for Medical Oncology 30(11): 1846
2019
ISSN/ISBN: 1569-8041
PMID: 31407000
DOI: 10.1093/annonc/mdz219
Accession: 069237595
PDF emailed within 0-6 h: $19.90
Related References
Kulke, M.H.; Ruszniewski, P.; Van Cutsem, E.; Lombard-Bohas, C.; Valle, J.W.; De Herder, W.W.; Pavel, M.; Degtyarev, E.; Brase, J.C.; Bubuteishvili-Pacaud, L.; Voi, M.; Salazar, R.; Borbath, I.; Fazio, N.; Smith, D.; Capdevila, J.; Riechelmann, R.P.; Yao, J.C. 2017: A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial Annals of Oncology: Official Journal of the European Society for Medical Oncology 28(6): 1309-1315Kulke, M.H.; Ruszniewski, P.; Van Cutsem, E.; Lombard-Bohas, C.; Valle, J.W.; De Herder, W.W.; Pavel, M.; Degtyarev, E.; Brase, J.C.; Bubuteishvili-Pacaud, L.; Voi, M.; Salazar, R.; Borbath, I.; Fazio, N.; Smith, D.; Capdevila, J.; Riechelmann, R.P.; Yao, J.C. 2019: A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial Annals of Oncology: Official Journal of the European Society for Medical Oncology 30(11): 1846
Ferolla, P.; Brizzi, M.P.; Meyer, T.; Mansoor, W.; Mazieres, J.; Do Cao, C.; Léna, H.é; Berruti, A.; Damiano, V.; Buikhuisen, W.; Grønbæk, H.; Lombard-Bohas, C.; Grohé, C.; Minotti, V.; Tiseo, M.; De Castro, J.; Reed, N.; Gislimberti, G.; Singh, N.; Stankovic, M.; Öberg, K.; Baudin, E. 2017: Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial LANCET. Oncology 18(12): 1652-1664
Chan, J.A.; Ryan, D.P.; Zhu, A.X.; Abrams, T.A.; Wolpin, B.M.; Malinowski, P.; Regan, E.M.; Fuchs, C.S.; Kulke, M.H. 2012: Phase i study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors Endocrine-Related Cancer 19(5): 615-623
Chan, J. A.; Ryan, D. P.; Zhu, A. X.; Abrams, T. A.; Wolpin, B. M.; Malinowski, P.; Regan, E. M.; Fuchs, C. S.; Kulke, M. H. 2012: Phase I study of pasireotide SOM 23 and everolimus RAD1 in advanced neuroendocrine tumors Endocrine Related Cancer 19(5): 615-623
Yao, J.; Wang, J.-y.; Liu, Y.; Wang, B.; Li, Y.-x.; Zhang, R.; Wang, L.-s.; Liu, L. 2014: A randomized phase Ii study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients Medical Oncology 31(12): 251
Pusceddu, S.; de Braud, F.; Concas, L.; Bregant, C.; Leuzzi, L.; Formisano, B.; Buzzoni, R. 2014: Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase Ii study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors Tumori 100(6): E286-E289
Yao, J.C.; Pavel, M.; Lombard-Bohas, C.; Van Cutsem, E.; Voi, M.; Brandt, U.; He, W.; Chen, D.; Capdevila, J.; de Vries, E.G.E.; Tomassetti, P.; Hobday, T.; Pommier, R.; Öberg, K. 2016: Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers from the Randomized, Phase IIi RADIANT-3 Study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34(32): 3906-3913
Fazio, N.; Buzzoni, R.; Delle Fave, G.; Tesselaar, M.E.; Wolin, E.; Van Cutsem, E.; Tomassetti, P.; Strosberg, J.; Voi, M.; Bubuteishvili-Pacaud, L.; Ridolfi, A.; Herbst, F.; Tomasek, J.; Singh, S.; Pavel, M.; Kulke, M.H.; Valle, J.W.; Yao, J.C. 2018: Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis Cancer Science 109(1): 174-181
Faggiano, A.; Modica, R.; Severino, R.; Camera, L.; Fonti, R.; Del Prete, M.; Chiofalo, M.G.; Aria, M.; Ferolla, P.; Vitale, G.; Pezzullo, L.; Colao, A. 2018: The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study Endocrine 62(1): 46-56
Lombard-Bohas, C.; Yao, J.C.; Hobday, T.; Van Cutsem, E.; Wolin, E.M.; Panneerselvam, A.; Stergiopoulos, S.; Shah, M.H.; Capdevila, J.; Pommier, R. 2015: Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase IIi RADIANT-3 trial Pancreas 44(2): 181-189
Cella, C.A.; Spada, F.; Galdy, S.; Frezza, A.M.; Catapano, M.; Funicelli, L.; Mancuso, P.; Zorzino, L.; Radice, D.; Calleri, A.; Fazio, N. 2015: R39Diffusion-Mri and angiogenic profiling in patients with advanced well-differentiated pancreatic neuroendocrine tumors treated with everolimus Annals of Oncology 26(Suppl 6): vi.254-vi
Toulmonde, M.; LeTourneau, C.; Cropet, C.; Italiano, A.; Bertucci, F.; Ray-Coquard, I.; Tredan, O.; Cassier, P.; Seigne, C.; Dela Fouchardiere, C.; Flechon, A.; Desseigne, F.; Frappaz, D.; Gomez-Roca, C.A.; Heudel, P.E. 2015: 31Lba Most My Own Specific Therapy A multicenter, randomized, open-label, phase Ii trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts European Journal of Cancer 51: S725-S726
Bauman, J.E.; Chen, Z.; Zhang, C.; Ohr, J.P.; Ferris, R.L.; McGorisk, G.M.; Brandt, S.; Srivatsa, S.; Chen, A.Y.; Steuer, C.E.; Shin, D.M.; Saba, N.F.; Khuri, F.R.; Owonikoko, T.K. 2022: A Multicenter Randomized Phase Ii Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer Cancers 14(11)
Rose, D.B.; Nellesen, D.; Neary, M.P.; Cai, B. 2017: Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic Journal of Medical Economics 20(4): 395-404
Pavel, M.E.; Becerra, C.; Grosch, K.; Cheung, W.; Hasskarl, J.; Yao, J.C. 2017: Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase IIi RADIANT-2 trial Clinical Pharmacology and Therapeutics 101(4): 462-468
Xu, J.; Li, J.; Bai, C.; Xu, N.; Zhou, Z.; Li, Z.; Zhou, C.; Jia, R.; Lu, M.; Cheng, Y.; Mao, C.; Wang, W.; Cheng, K.; Su, C.; Hua, Y.; Qi, C.; Li, J.; Wang, W.; Li, K.; Sun, Q.; Ren, Y.; Su, W. 2019: Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: a Multicenter, Single-Arm, Open-Label, Phase Ib/Ii Trial Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25(12): 3486-3494
Dasari, A.; Phan, A.; Gupta, S.; Rashid, A.; Yeung, S.-C.J.; Hess, K.; Chen, H.; Tarco, E.; Chen, H.; Wei, C.; Anh-Do, K.; Halperin, D.; Meric-Bernstam, F.; Yao, J. 2015: Phase i study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors Endocrine-Related Cancer 22(3): 431-441
Decker, T.; Söling, U.; Hahn, A.; Maintz, C.; Kurbacher, C.Martin.; Vehling-Kaiser, U.; Sent, D.; Klare, P.; Hagen, V.; Chiabudini, M.; Falkenstein, J.; Indorf, M.; Runkel, E.; Potthoff, K. 2020: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer Bmc Cancer 20(1): 286
Casciano, R.; Chulikavit, M.; Perrin, A.; Liu, Z.; Wang, X.; Garrison, L.P. 2012: Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States Journal of Medical Economics 15(Suppl 1): 55-64